Matinas Biopharma Holdings, INC 8-K filings

Matinas BioPharma announced its first quarter 2024 financial results, highlighting a recent $10 million financing and ongoing partnership discussions for its lead drug candidate, MAT2203.

Matinas BioPharma has entered into agreements for a $10 million registered direct offering of common stock and warrants to healthcare-focused institutional investors.

Matinas BioPharma Holdings, Inc. has released an updated corporate presentation to be used at upcoming conferences and investor meetings.

Matinas BioPharma reports its 2023 financial results and provides a business update, emphasizing the progress of its LNC platform and the MAT2203 program, including a clear regulatory pathway and FDA agreement on the Phase 3 trial.

Matinas BioPharma's oral LNC-docetaxel formulation demonstrated a significantly improved safety profile compared to IV-docetaxel in a preclinical study, with mice maintaining body weight while receiving a higher dose.

Matinas BioPharma reports successful clinical outcomes in three patients with serious invasive fusarium infections treated with their oral antifungal drug candidate, MAT2203.

Matinas BioPharma has successfully regained compliance with NYSE American listing standards due to sustained improvement in its stock price.

Matinas BioPharma reports positive results from its compassionate use program for MAT2203, showing reversal of renal impairment and clinical improvement in patients with invasive fungal infections.

Matinas BioPharma has reached an agreement with the FDA on the design of a Phase 3 trial for its MAT2203 product candidate for the treatment of invasive aspergillosis.